Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial

详细信息    查看全文

• 作者：K. Gert van Houwelingen^a ; Ming Kai Lam^a ; Marije M. Lö ; wik^a ; Peter W. Danse^b ; R. Melvyn Tjon Joe Gin^b ; Gillian A. Jessurun^c ; Rutger L. Anthonio^c ; Hanim Sen^a ; Gerard C.M. Linssen^d ; Maarten J. IJzerman^e ; Carine J.M. Doggen^e ; Clemens von Birgelen^a ; ^e ; ^{c.vonbirgelen@mst.nl}
• 关键词：Percutaneous coronary intervention ; Drug-eluting stent ; Myocardial infarction ; Acute coronary syndrome ; DUTCH PEERS (TWENTE II) trial ; Platinum-chromium everolimus-eluting stent ; Cobalt-chromium zotarolimus-eluting stent ; Promus Element stent ; Resolute Integrity stent
• 刊名：Revista Española de Cardiología (English Edition)
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：69
• 期：12
• 页码：1152-1159
• 全文大小：343 K
• 卷排序：69

文摘

In acute myocardial infarction (MI), novel highly deliverable drug-eluting stents (DES) may be particularly valuable as their flexible stent designs might reduce device-induced traumas to culprit lesions. The aim of the study was to assess the safety and efficacy of percutaneous coronary interventions with 2 novel durable polymer-coated DES in patients with acute MI.MethodsThe prospective, randomized DUTCH PEERS (TWENTE II) multicenter trial compares Resolute Integrity and Promus Element stents in 1811 all-comer patients, of whom 817 (45.1%) were treated for ST-segment elevation MI or non—ST-segment elevation MI and the 2-year outcome is available in 99.9%. The primary clinical endpoint is target vessel failure (TVF), a composite of cardiac death, target vessel related MI, or target vessel revascularization.ResultsOf all 817 patients treated for acute MI, 421 (51.5%) were treated with Resolute Integrity and 396 (48.5%) with Promus Element stents. At the 2-year follow-up, the rates of TVF (7.4% vs 6.1%; P = .45), target lesion revascularization (3.1% vs 2.8%; P = .79), and definite stent thrombosis (1.0% vs 0.5%; P = .69) were low for both stent groups. Consistent with these findings in all patients with acute MI, outcomes for the 2 DES were favorable and similar in both, with 370 patients with ST-segment elevation MI (TVF, 5.1% vs 4.9%; P = .81) and 447 patients with non—ST-segment elevation MI (TVF, 9.0% vs 7.5%; P = .56).ConclusionsResolute Integrity and Promus Element stents were both safe and efficacious in treating patients with acute MI. The present 2-year follow-up data underline the safety of using these devices in this particular clinical setting.